ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1467

Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: Non-Invasive Arterial Health Testing to Assess Subclinical Risk of Cardiovascular Disease

Erin Scanlon1, Rekha Mankad2, Cynthia S. Crowson3, Iftikhar Kullo4, Sharon Mulvagh2, Eric L. Matteson1, Zoran Kvrgic1 and John M. Davis III5, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 3Health Sciences Research, Mayo Clinic, Rochester, MN, 4Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Atherosclerosis, Cardiovascular disease, rheumatoid arthritis (RA) and risk assessment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Measures of arterial health may be useful in assessing the risk of atherosclerotic cardiovascular disease (ASCVD) in patients with rheumatoid arthritis (RA). The objective of this study was to determine if our innovative arterial health testing panel would identify early ASCVD that is not reflected in traditional CV risk scores in patients with RA. The AHA/ACC Pooled Cohort Equation (estimated 10-year CV risk %) is used to classify patients as low/intermediate/high risk. Our study evaluated early CV disease (plaque presence, carotid intima media thickness) using non-invasive arterial health testing in RA patients classified in the low/intermediate CV risk category.

Methods:   50 patients with RA underwent non-invasive arterial health testing (brachial artery reactivity testing, pulse wave velocity, and carotid intima media thickness [CIMT] and plaque presence) and calculation of the estimated 10 year CV risk (%) using the AHA/ACC Pooled Cohort Equation. Comparisons between non-invasive arterial health measures and the low/intermediate/high risk category as identified by the AHA/ACC Pooled Cohort Equation (10-year risk %) were performed using chi-square and rank sum tests. Descriptive statistics were examined to determine whether we could identify early CV disease (plaque presence) in patients typically classified as low or intermediate risk.

Results:   In the 50 patients (mean age: 57.5 years; 76% female, mean RA disease duration: 6.4 years), the AHA/ACC Pooled Cohort Equation (10-year risk %, as measured as low <4%, intermediate 4-7.5%, and high >7.5%) was used to estimate CV risk. Carotid plaques were found in 7 of 21 (33%) patients with low AHA/ACC risk, 11 of 15 (73%) patients with intermediate AHA/ACC risk, and 2 of 8 (25%) patients with high AHA/ACC risk. Plaque in the intermediate AHA/ACC risk group was identified as mild in 9 (82%) and severe in 2 (18%) of the 11 patients with plaques. Brachial artery reactivity testing showed that hyperemic forearm flow was highest in the high risk category (median 712 compared to 510 in intermediate risk and 459 in low risk, p=0.048). No significant differences were identified with measures of arterial stiffness, such as pulse pressure, aortic pulse wave velocity, aortic augmentation index and corrected aortic augmentation index between low, intermediate, and high risk categories. The mean CIMT was highest in the high risk group (median 0.9 compared to 0.8 in intermediate and 0.7 in low risk, p=0.006), and maximal common carotid IMT highest in the high risk group as well (p=0.01).

Conclusion:   Among patients with RA considered to have intermediate CV risk by the AHA/ACC Pooled Cohort Equation (4-7.5% AHA/ACC risk), non-invasive arterial health testing identified a high proportion of patients with both mild and severe carotid plaques. The presence of carotid plaques may identify early ASCVD that is not adequately predicted by standard CV risk scores calculators.


Disclosure: E. Scanlon, None; R. Mankad, None; C. S. Crowson, None; I. Kullo, None; S. Mulvagh, None; E. L. Matteson, Regeron, 2,Amgen, 2,Celgene, 2,Genentech and Biogen IDEC Inc., 2,Mesoblast, 2,Pfizer Inc, 2,Novartis Pharmaceutical Corporation, 2,Roche Pharmaceuticals, 2,Glaxo Smith Kline, 2,Up-To-Date, 9; Z. Kvrgic, None; J. M. Davis III, Pfizer Inc, 2,Genentech and Biogen IDEC Inc., 2.

To cite this abstract in AMA style:

Scanlon E, Mankad R, Crowson CS, Kullo I, Mulvagh S, Matteson EL, Kvrgic Z, Davis JM III. Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: Non-Invasive Arterial Health Testing to Assess Subclinical Risk of Cardiovascular Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-risk-assessment-in-persons-with-rheumatoid-arthritis-non-invasive-arterial-health-testing-to-assess-subclinical-risk-of-cardiovascular-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-assessment-in-persons-with-rheumatoid-arthritis-non-invasive-arterial-health-testing-to-assess-subclinical-risk-of-cardiovascular-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology